Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
Commercial Sponsor
Pfizer
Summary
This is a non-randomised trial assessing the clinical benefits of Elranatamab in people with Multiple Myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody.
The trial has two cohorts, both will receive the BCMA-CD3 bispecific antibody Elranatamab (PF-06863135).